Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Resectable Localized Prostate Cancer
NCT06408298Phase 1Recruiting
- Start
- Jan 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in prostate cancer (PCa) comparing Hydroxychloroquine with Placebo (2 arms). Primary endpoint: Change in expression of markers of autophagy at Day 30. Started Jan 2026; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06408298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408298.